Related Experiment Videos
[Cicletanine administered with other antihypertensive agents].
D Grimberg1, T Tarrade, E Deschamps de Paillette
1Hôpital Tenon, Paris.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|November 1, 1989
Summary
Cicletanine effectively lowers blood pressure in patients with essential hypertension inadequately controlled by other drugs. This antihypertensive medication demonstrated good tolerability and reduced symptoms like headaches and dizziness.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Essential hypertension often requires combination therapy for adequate control.
- Existing antihypertensive regimens (beta-blockers, central agents, nifedipine) may be insufficient for some patients.
Purpose of the Study:
- To evaluate the antihypertensive effectiveness of adding cicletanine to existing treatments.
- To assess the clinical and biochemical safety of cicletanine in combination therapy.
Main Methods:
- 84 patients with permanent essential hypertension received cicletanine in addition to their current beta-blocker, central agent, or nifedipine.
- Treatment duration was 3 months, with blood pressure and safety parameters monitored.
Main Results:
- Significant reductions in systolic and diastolic blood pressure were observed across all three combination groups.
- Blood pressure normalization was achieved in 63% (beta-blockers), 43% (central agents), and 50% (nifedipine) of patients.
- Cicletanine addition improved functional symptoms and was generally well-tolerated with minor side effects.
Conclusions:
- Cicletanine is an effective antihypertensive agent when added to beta-blockers, central agents, or nifedipine.
- Combination therapy with cicletanine demonstrates a favorable safety profile and improves patient symptoms.